Whitehawk Therapeutics Inc. Ordinary Shares WHWK 深 滬
已收盤 12-05 16:00:00 美东时间
2.49
-0.070
-2.73%
華盛通- 最 高2.59
- 今 開2.56
- 成交量 9.27万股
- 最 低 2.49
- 昨 收 2.56
- 總市值 1.17亿
- 52周最高 3.812
- 市盈率 靜 --
- 換手率 0.20%
- 52周最低 1.39
- 委 比 -93.76%
- 總股本 4712.84万
- 歷史最高 65.25
- 量 比 0.37
- 振 幅 3.91%
- 歷史最低 1.21
- 每 手 1
- 風險率 0.47%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Whitehawk Therapeutics Appoints Margaret Dugan, MD, as Chief Medical Officer
Dr. Dugan brings extensive clinical development leadership to Whitehawk as ADC programs near the clinic MORRISTOWN, N.J., Dec. 1, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: W...
12-01 21:00
Whitehawk Therapeutics Q3 EPS $(0.26) Misses $0.07 Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.26) per share which missed the analyst consensus estimate of $0.07 by 488.06 percent. This is a 43.48 percent increase over losses of $(0.46) per
11-06 21:37
Whitehawk Therapeutics Presents Data From Protein Tyrosine Kinase 7 Analysis From Over 157K Tumor Samples At 2025 AACR-NCI-EORTC International Conference On Molecular Targets And Cancer Therapeutics
Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments,
10-25 00:34
美股牛股 | PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；生物技术股WHWK涨超24%
PRAX暴涨逾180%！在原发性震颤治疗领域取得重大突破；WHWK涨超24%，与Tempus AI建立战略伙伴关系，共同推进肿瘤研究领域发展>>
10-17 17:43
Tempus AI Enters A Multi-Year Collaboration With Whitehawk Therapeutics To Leverage Tempus' Real-World Data And AI Capabilities For Biomarker-Driven Cancer Research
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine, today announced a multi-year collaboration with Whitehawk Therapeutics, Inc. (NASDAQ:WHWK), an oncology
10-16 20:32
Whitehawk Therapeutics to Participate in Upcoming Investor Conferences
MORRISTOWN, N.J., Sept. 2, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to e...
09-02 20:00
Whitehawk Therapeutics Q2 EPS $(0.76) Misses $0.49 Estimate
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly losses of $(0.76) per share which missed the analyst consensus estimate of $0.49 by 254.16 percent. This is a 40.74 percent decrease over losses of $(0.54) per
08-07 20:11
Whitehawk Therapeutics to Participate in H.C. Wainwright "HCW@Home" Series
MORRISTOWN, N.J., June 19, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to e...
06-19 20:00
Whitehawk Therapeutics Q1 EPS $1.83 Beats $(0.46) Estimate, Sales $7.14M Up From $5.35M YoY
Whitehawk Therapeutics (NASDAQ:WHWK) reported quarterly earnings of $1.83 per share which beat the analyst consensus estimate of $(0.46) by 497.83 percent. This is a 369.12 percent increase over losses of $(0.68) per
05-09 04:47
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals
MORRISTOWN, N.J., March 26, 2025 /PRNewswire/ -- Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), an oncology therapeutics company applying advanced technologies to established tumor biology to ...
03-26 20:00
